
Novel Therapeutic Nanobody
Acts selectively in p53-deficient cells. Destroys cancer.*
Our Focus
Targeting the Most Aggressive Cancers

- Breast cancer causes ~670,000 deaths annually with 2.3 million new cases worldwide (WHO).
- Triple-negative breast cancer (TNBC) is highly aggressive, with lower survival rates and few targeted treatment options.
- Our lead candidate, PHP53-nb selectively targets p53-deficient tumors using the uPAR-dependent entry to promote cell apoptosis, addressing a key driver of TNBC.
- PHP53-nb is a patented nanobody with no linkers that is internalized within cancer cells exploiting p53’s dysfunction to impair metastasis and induce apoptosis.


Mechanism of Action
PHP53-nb is a nanobody which specifically targets cancer cells. It:
Enters the cell through uPAR-driven endocytosis exploiting uPAR over-expression in p53 deficient tumors
- Triggers proteotoxic stress leading to apoptosis of cancer cells
Our Platform and Pipeline
Our nanobody platform can be used for a variety of therapeutic applications and has several advantages over traditional monoclonal antibodies.
Multi-indication Payload: 3-NAntC Peptide (TNBC)
Therapeutic Humanized Camelid Nanobody: GEN01-AD
Therapeutic Humanized Camelid Nanobody: PHP53-nb (TNBC & other cancers)
Discovery
Preclinical
Phase 1
About PHP Biotech
A team of dedicated experts pushing what’s possible in cancer treatment
We are a US-based biotech company founded by innovative healthcare entrepreneurs and powered by a world-class scientific & research team, global CROs and CDMOs, who specialize in nanobody and translational biotechnology and are instrumental in our critical research.
Our lead candidate, PHP53-nb, is a first-in-class humanized nanobody showing strong anti-tumor efficacy, low toxicity, and a novel mechanism of action.

